Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Entegris Inc (ENTG) vs Heron Therapeutics Inc (HRTX) Price & Performance

Entegris IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Entegris Inc vs Heron Therapeutics Inc — how do they compare? Entegris Inc trades at $160.97 (market cap $22.95B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Entegris Inc is far larger — about 373.4× Heron Therapeutics Inc's market cap, and Entegris Inc pays a 0.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

ENTGHRTX
Market Cap
$22.95B$61.47M
Sector
TechnologyHealth
52-Week High
$184.00$1.49
52-Week Low
$68.80$0.32
Enterprise Value
$26.16B$168.21M
Dividend Yield
0.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Entegris Inc

ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.

Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX